Traders should monitor whether the new technology investments under Scale51 can generate revenue to offset declining core operations. The deteriorating Adjusted EBITDA despite revenue declines suggests structural cost issues. Upcoming developments on Scentech acquisition and Enquantum integration may provide catalysts.
Price Chart
Executive Summary
Reliance Global Group (EZRA) reported 2025 financial results showing a reduced net loss of $7.0M (from $9.1M in 2024) but declining commission income of $12.4M (down 12% YoY) due to divestitures. The company launched its Scale51 tech growth strategy, invested in post-quantum cybersecurity firm Enquantum Ltd., and entered a non-binding term sheet to acquire AI diagnostics company Scentech Medical. Despite improved balance sheet metrics, Adjusted EBITDA worsened to -$1.6M from -$0.3M.
Key Financial Metrics
Key Facts
- Net loss improved to $7.0M in 2025 from $9.1M in 2024, primarily due to gains on divestitures and absence of prior-year impairments.
- Commission income declined 12% YoY to $12.4M due to sale of Fortman Insurance Services, Employee Benefits Solutions, and U.S. Benefits Alliance.
- Adjusted EBITDA deteriorated to -$1.6M in 2025 from -$0.3M in 2024, reflecting lower revenue and higher operating costs.
- Unrestricted cash increased 250% to $1.3M; working capital improved 351% to $1.9M; stockholders' equity rose 114% to $6.4M.
- Company launched Scale51 technology platform and EZRA International Group, completed investment in Enquantum Ltd., and signed non-binding term sheet for majority stake in Scentech Medical.
Financial Impact
Revenue down $1.7M YoY, net loss improved by $2.1M due to one-time gains, but core operational profitability (Adjusted EBITDA) declined by $1.3M. Balance sheet strengthened with $3.4M increase in equity.
Risk Factors
- Core insurance business is shrinking with commission income down 12% and Adjusted EBITDA deteriorating.
- Technology investments (Enquantum, Scentech) are early-stage and non-binding; commercial success and integration risks are high.
- Heavy reliance on non-cash items (e.g., $5.7M in share-based compensation) inflates expenses without immediate cash impact but increases dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253306 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.18 | awaiting T+5 | — | $2.23 (+2.29%) |
Oct 22, 2026 4d ago | Press Release | $2.29 | awaiting T+5 | — | $2.23 (−2.41%) |
Oct 15, 2026 11d ago | SC 13D/A | $2.48 $2.29 | ▲ +7.86% | ▲ +6.85% | $2.23 (+10.08%) |
Oct 15, 2026 11d ago | SC 13D/A | $2.48 $2.29 | ▲ +7.86% | ▲ +6.85% | $2.23 (+10.08%) |
Oct 13, 2026 13d ago | 8-K | $2.30 $2.36 | ▲ +2.61% | ▲ +3.76% | $2.23 (−3.04%) |
Oct 5, 2026 21d ago | 8-K | $2.50 $2.30 | ▼ −8.00% | ▼ −7.86% | $2.23 (−10.80%) |
Sep 16, 2026 5w ago | 8-K | $2.68 $2.69 | ▲ +0.37% | ▼ −2.19% | $2.23 (−16.79%) |
Sep 11, 2026 6w ago | 8-K | $2.70 $2.62 | ▼ −2.96% | ▼ −2.74% | $2.23 (−17.41%) |
Jul 30, 2026 12w ago | Press Release | $1.82 $2.55 | ▼ −40.11% | ▼ −36.60% | $2.23 (−22.53%) |
Jun 3, 2026 20w ago | 8-K | $3.71 $3.48 | ▼ −6.20% | ▼ −2.38% | $2.23 (−39.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers